- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01095198
Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)
Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation
Up to 30% of Canadian women do not participate in Pap smear screening for cervical cancer prevention despite many being members of family practices and having access to family physicians. One reason is reluctance to undergo pelvic examination.
The investigators purpose is to determine whether the offer of vaginal self sample collection for oncogenic human papillomavirus (HPV) testing increases participation in cervical cancer screening compared to repeat reminder for Pap smear testing among female family practice members who have not previously responded to invitations for Pap testing.
Study Overview
Status
Intervention / Treatment
Detailed Description
Pap smear screening for cervical cancer precursors has substantially reduced the incidence of invasive cervical cancer in Canada. While regular Pap screening can give up to 90% protection against cervical cancer, about 30% of Canadian women do not participate in regular screening.
Pap screening in Ontario is opportunistic. There are women who have family doctors and regularly present for other medical issues at their physician's office but forego Pap smear testing.
Numerous studies have shown that women are able to self collect vaginal samples, and that these samples can be tested for the presence of oncogenic human papillomavirus. A recent meta-analysis showed that HPV testing through physician collected samples had a sensitivity of 80%-90% for detection of cervical intraepithelial neoplasia (CIN) 2 or worse, and a specificity of 86%-95%. In comparison, a meta-analysis of self collected vaginal samples tested for HPV showed a sensitivity of 74% and a specificity of 88%.
Studies have reported that women find self collection acceptable. However, we have found that many women are more comfortable if a health care professional is available to help if needed, and so this option should be provided for self-testing.
We are proposing a randomized controlled trial to see whether (a) the offer of a vaginal self collection kit together with a second reminder for Pap testing will increase cervical screening participation amongst "never-screened" and "hard to reach" women, as compared to (b) a second reminder letter alone.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S4L8
- McMaster University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- members of consenting family physicians identified through OSCAR EMR
- overdue for Pap smear testing
- have not presented for Pap smear screening after 1 reminder letter
Exclusion Criteria:
- currently attending colposcopy clinic
- institutionalized
- without a cervix
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 2nd Reminder Letter
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
|
Women in both groups will receive a letter informing them that they are due for cervical screening.
This is a standard letter, and is signed by the patient's individual family physicians.
It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
Other Names:
|
EXPERIMENTAL: Offer of Vaginal Self Collection
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
|
Women in both groups will receive a letter informing them that they are due for cervical screening.
This is a standard letter, and is signed by the patient's individual family physicians.
It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
Other Names:
Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing.
They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study.
The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing.
Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff.
The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
uptake of screening invitation
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cervical Intraepithelial Neoplasia (CIN) 3 identified
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alice Lytwyn, MD, FRCPC, McMaster University
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCTself
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedHigh-grade Cervical Intraepithelial NeoplasiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
Genexine, Inc.CompletedCervical Intraepithelial Neoplasia 3Korea, Republic of
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
University Medical Centre MariborRecruitingCervical Intraepithelial Neoplasia Grade 2 | DNA MethylationSlovenia
-
Onconix, IncUnknownCervical Cancer | Cervical Intraepithelial Neoplasia III | Cervical Intraepithelial Neoplasia IIUnited States
Clinical Trials on 2nd reminder letter for Pap testing
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed
-
Médecins du MondeNational Cancer Institute, FranceUnknown
-
UNC Lineberger Comprehensive Cancer CenterCompletedColorectal Cancer | Colorectal Cancer Screening
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingHPV Infection | Oral Cavity Disease | Dysplasia AnusSpain
-
Brown UniversityCompleted
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedCervical Cancer | Uterine Cervical Neoplasms | Human PapillomavirusUnited States
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARecruiting
-
University Medical Center GroningenInternational Centre for Diarrhoeal Disease Research, Bangladesh; Uganda Cancer... and other collaboratorsCompletedCervix Cancer | HPV Infection | Cervical DysplasiaUganda